Concepedia
Statistics
Publications
7
Citations
239
H-Index
Active since
2010
Affiliations
Cadila Pharmaceuticals (India)(Current)
Banaras Hindu University
Indian Institute of Technology BHU
Post Graduate Institute of Medical Education and Research
Indian Institute of Technology Guwahati
Bakulesh Khamar is an author at Cadila Pharmaceuticals (India) specializing in infectious diseases, life sciences, and immunology.
Publications per year
2010–2022
Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial
Surendra K. Sharma, Kiran Katoch, Rohit Sarin et al. · Scientific Reports · 2017 · 109 citations · Full text
Life Sciences, Immunology, Infectious Diseases +9
A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer
Chandra P. Belani, Banya Chakraborty`, Rajiv Modi et al. · Annals of Oncology · 2016 · 51 citations · Full text
Medicine, Oncology, Pharmacology +8
Preservation of Bioavailability of Ingredients and Lack of Drug-Drug Interactions in a Novel Five-Ingredient Polypill (Polycap™)
Anil Patel, Tarang Shah, Gaurang Shah et al. · American Journal of Cardiovascular Drugs · 2010 · 32 citations
Pharmacy, Pharmaceutics, Pharmacokinetics +10
Leishmania donovani evades Caspase 1 dependent host defense mechanism during infection
Gundappa Saha, Bakulesh Khamar, Om Prakash Singh et al. · International Journal of Biological Macromolecules · 2018 · 17 citations
Life Sciences, Immunology, Infectious Diseases +16
A Clinical Trial of the Intradermal TLR2 Agonist CADI-05 for BCG Recurrent and Unresponsive Non-Muscle Invasive Bladder Cancer
Michael A. O’Donnell, Sharwan Kumar Singh, Rajeev Sood et al. · Bladder Cancer · 2019 · 10 citations · Full text
Medicine, Oncology, Urology +16
1–5 of 7